We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    00977444
Previous Study | Return to List | Next Study

Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment (EFO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00977444
Recruitment Status : Unknown
Verified January 2010 by Nucitec.
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2009
Last Update Posted : January 20, 2010
National Council of Science and Technology, Mexico
Information provided by:

Brief Summary:


Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee.

A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: kondrium Drug: kondrium f Drug: methyl prednisolone (corticosteroid) Phase 2 Phase 3

Detailed Description:

The WOMAC osteoarthritis index is a validated, multidimensional, disease specific, health status measure. It probes clinically important patient relevant symptoms in the areas of pain, stiffness and physical function in patients with hip and/or knee osteoarthritis. It consists of 24 questions in three separated subscales (5 questions on pain subscale, 17 questions on physical function subscales and 2 questions on stiffness subscale), each scored in analog scale from 0 to 10 points (0 representing no pain, 10 representing extreme pain). Each subscale score was weighed 10 points, thus 30 was the maximum punctuation for WOMAC total score.

The Lequesne index is a 10-question interview-style survey given to patients with osteoarthritis of the knee. It has 5 questions pertaining to pain or discomfort, 1 question dealing with maximum distance walked, and 4 questions about daily activities. The total questionnaire is scored on a 0 to 24 scale, with lower scores meaning less functional impairment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment
Study Start Date : November 2007
Estimated Primary Completion Date : February 2009
Estimated Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: kondrium
intraarticular injections once month
Drug: kondrium
intraarticular injections once month

Experimental: kondrium f Drug: kondrium f
intraarticular injections once month

Active Comparator: corticosteroid
intraarticular injections once month
Drug: methyl prednisolone (corticosteroid)
intraarticular injections once month
Other Name: corticosteroid

Primary Outcome Measures :
  1. The primary efficacy variable is the change from baseline to final assessment in the Western Ontario and McMastern University OA index (WOMAC), and Lequesne´s functional index. [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age > 40 years
  • symptomatic evidence of OA in the knee for at least 1 year
  • radiographic evidence of Kellgren and Lawrence grade II to IV OA of the knee
  • no intra-articular injection of corticosteroids within the last 3 months

Exclusion Criteria:

  • any history of adverse reaction to the study drugs
  • current pregnancy status
  • uncontrolled hypertension
  • active infection
  • undergone surgery/arthroscopy within three months
  • diagnosis of radiographic OA of Kellgren and Lawrence grade I

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00977444

Layout table for location information
Hospital San Jose
Queretaro, Mexico
Sponsors and Collaborators
National Council of Science and Technology, Mexico
Layout table for investigator information
Principal Investigator: Ricardo Amador, PhD Hospital San Jose
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sandra Garcia, Cindetec
ClinicalTrials.gov Identifier: NCT00977444    
Other Study ID Numbers: PEE-002-2007
First Posted: September 15, 2009    Key Record Dates
Last Update Posted: January 20, 2010
Last Verified: January 2010
Keywords provided by Nucitec:
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents